In expanded populations, comparing semaglutide versus sitagliptin for the composite outcome of myocardial infarction or stroke yielded a hazard ratio of 0.82 (95% confidence interval (CI) 0.74 to 0.91), and comparing tirzepatide versus dulaglutide for the composite outcome including mortality yielded a hazard ratio of 0.87 (95% CI 0.75 to 1.01)
No evidence emerged, moreover, that patients psychiatric history had an impact on risk
Injectable vs Tablet vs "Sublingual" GLP-1 Options: What to Know This comparison is provided for educational context only and does not imply availability, equivalence, or endorsement of non-injectable GLP-1 formats by IVY RX
Evidence remains largely preclinical, but findings indicate possible benefits in reducing inflammation and aiding recovery in digestive tissues, especially in conditions involving ulcers or irritation
GHK-Cu is generally considered promising in research settings, but all peptide therapies should be discussed with a licensed medical provider before use
Additionally, if you notice delayed wound healing, hair thinning, or easy bruising developing after starting therapy, discuss these findings with your provider, as they may indicate nutritional factors or other issues requiring attention